COVID-19 vaccine developer Novavax (NASDAQ:NVAX) enters into an agreement with B. Riley FBR for the at-the-market sale of up the $250M of its common stock.

The agent will earn a 2% commission for its efforts.

Shares down 1% after hours.

READ FULL ARTICLE HERE